• Coronavirus

Dr. Quay speaks at TFAS Capitol Hill Lecture on COVID origins

Play Video

Dr. Steven Quay, alongside Senator Rand Paul and Richard H. Ebright, a professor at Rutgers University, thoroughly explores the lab leak theory surrounding COVID-19 from a scientific viewpoint.

Dr. Quay’s analysis focuses on the genetic evidence found within the virus, similar to forensic evidence at a crime scene. He emphasizes the idea of a “molecular clock” in viruses, where mutations accumulate over time. By comparing SARS-CoV-2 with previous viruses such as SARS, he identifies significant genetic differences that suggest a longer evolutionary timeline than proposed by the wet market theory.

Senator Rand Paul raises questions to Dr. Quay about a DARPA (Defense Advanced Research Projects Agency) research proposal, prompting concerns from Dr. Quay regarding the safe handling of viruses. He highlights instances where risky virus research, potentially involving SARS-CoV-2, was conducted in environments with lower security standards than recommended.

Watch the full hour here:
https://www.youtube.com/watch?v=uj-PtkM1_cU

Learn more about The Fund for American Studies go to TFAS.org/CHLS.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Results: Endoxifen Reduces Breast Density

November 8, 2024

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Taiwan based scientist makes case for lab origin for COVID

November 7, 2024

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

October 31, 2024

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Join Dr. Quay’s ElevatorMedicine™ and get FREE, QUICK TIPS for better living, health, and wellness that take less time than riding an elevator!